Key result
SGLT2 inhibitors reduce worsening heart failure events across the LVEF spectrum and protect kidney function.
Why the study?
This narrative review was conducted to synthesize contemporary evidence on the cardiorenal mechanisms, clinical efficacy, safety, and practical implementation of SGLT2 inhibitors across the heart failure spectrum.
Do sodium-glucose cotransporter 2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients across the spectrum of heart failure?
Do sodium-glucose cotransporter 2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients across the spectrum of heart failure?
This narrative review synthesizes evidence confirming that SGLT2 inhibitors provide consistent cardiovascular and renal protection across the entire heart failure ejection fraction spectrum through integrated hemodynamic, tubular, and cellular mechanisms.
Supports SGLT2 inhibitor use across HF LVEF spectrum; confirms cardiorenal benefits from major RCTs while leaving implementation questions open.
This narrative review aims to synthesize contemporary evidence on the cardiorenal mechanisms, clinical efficacy, safety, and practical implementation of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in heart failure (HF). A focused narrative literature search was conducted using PubMed/MEDLINE and major international professional society guideline repositories, primarily covering publications from January 2019 to September 1, 2026. Priority was given to randomized controlled trials, prespecified trial analyses, meta-analyses, human mechanistic studies, and contemporary international clinical practice guidelines. Major randomized controlled trials consistently demonstrated the cardiovascular and renal benefits of SGLT2 inhibition across the HF spectrum, although the magnitude and certainty of renal benefits varied across populations and outcomes. The DAPA-HF and EMPEROR-Reduced trials established reductions in worsening HF events and HF hospitalizations among patients with heart failure with reduced ejection fraction (HFrEF), whereas the EMPEROR-Preserved and DELIVER trials extended these benefits to patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). The EMPULSE trial supported the initiation of empagliflozin following clinical stabilization during hospitalization for acute HF, while dedicated renal outcome trials demonstrated clinically meaningful kidney protection. Mechanistically, SGLT2 inhibition reduces sodium and glucose reabsorption in the renal proximal tubule, restores tubuloglomerular feedback, lowers intraglomerular pressure, and promotes modest natriuresis and osmotic diuresis. Additional mechanisms involving erythropoiesis, metabolic regulation, mitochondrial function, and anti-inflammatory and antifibrotic effects may contribute to cardiovascular protection, although several pathways remain supported primarily by preclinical and translational evidence rather than definitive human studies. Important safety considerations include genital mycotic infections, volume depletion, and the rare but clinically significant risk of euglycemic diabetic ketoacidosis.
No takes yet. Share an insight, caveat, or question.
Tarigan et al. (2026) conducted a review in Heart Failure (HFrEF, HFmrEF, HFpEF, and acute HF) and Chronic Kidney Disease. Sodium-glucose cotransporter 2 inhibitors (dapagliflozin, empagliflozin, sotagliflozin) vs. Placebo on top of guideline-directed medical therapy was evaluated on Worsening heart failure events, heart failure hospitalizations, cardiovascular death, and kidney disease progression. SGLT2 inhibitors consistently reduce worsening heart failure events and hospitalizations across the LVEF spectrum (HR 0.74 to 0.82 in major trials) and provide significant kidney protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: